BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BL-8040, for …Fort Mills TimesPre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow metastasis of …
|
Pfizer Keeping the ADC Faith: Potential $635M CytomX Deal
BioWorld Online … antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting CD22, administered in combination with Rituxan (rituximab, Roche AG and Biogen Idec Inc.), in relapsed or refractory CD22-positive aggressive non-Hodgkin’s lymphoma (NHL). |
|
Neuronas obtenidas a partir de células madre de cordón .
El Mundo.es Algunas como los anticuerpos monoclonales, alemtuzumab, daclizumab, o daclizumab, han mostrado en ensayos clínicos mayor eficacia que el interferón beta (la terapia clásica), y otros, en vías de aprobación, como fingolimob y BG12, aportan la ventaja de … |
CytomX Snags $25M From Pfizer to Make Souped-Up AntibodiesXconomyPfizer was tripped up a couple years ago, when safety concerns emerged around the first drug ever approved that could combine the targeting ability of an antibody with a toxin to give it …
Moneycontrol.com |
Celgene Corporation gets USFDA approves for REVLIMID
Moneycontrol.com The approval was based on the results of MCL-001, a phase II, multi-center, single arm, open label study evaluating lenalidomide in 134 patients with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline (or … FDA Approves Lenalidomide for the Treatment of Mantle Cell LymphomaOncLive Revlimid Gains New Lymphoma IndicationMonthly Prescribing Reference FDA clears Celgene’s sNDA for mantle cell lymphoma drug candidatePharmaceutical Business Review |
|
Biosimilars And Follow-On Biologics: World Market 2013-2023
Sacramento Bee Our study forecasts revenues of prominent biosimilar agents at molecular level: • Rituximab • Infliximab • Trastuzumab. There you discover how high sales can go, to 2023, with individual forecasts. You see what’s happening, understanding trends … |
Moneycontrol.com |
FDA Approves Lenalidomide for the Treatment of Mantle Cell Lymphoma
OncLive The MCL-001 study enrolled 134 patients with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline (or mitoxantrone), and bortezomib alone or in combination and who had documented relapsed or refractory disease. Celgene Corporation gets USFDA approves for REVLIMIDMoneycontrol.com FDA clears Celgene’s sNDA for mantle cell lymphoma drug candidatePharmaceutical Business Review Revlimid Gains New Lymphoma IndicationMonthly Prescribing Reference |
|
Cowen Questions Sales Growth of Biogen Idec’s MS Drug Tecfidera
SmallCap Network AVONEX® (interferon beta-1a), TYSABRI® (natalizumab), and RITUXAN® (rituximab) are Biogen’s other primary drugs in the MS indication. These three brought in the vast majority of the company’s $1.4 B in quarterly revenues ($736 million, $275 million, … |
iStockAnalystRevlimid Gains New Lymphoma IndicationMonthly Prescribing ReferenceThe new indication approval is based on the results of a Phase 2, multicenter, single-arm, open-label study evaluating lenalidomide in patients (N=134) with MCL who had rec…
|
Biosimilars And Follow-On Biologics: World Market 2013-2023
The Herald | HeraldOnline.com Our study forecasts revenues of prominent biosimilar agents at molecular level: • Rituximab • Infliximab • Trastuzumab. There you discover how high sales can go, to 2023, with individual forecasts. You see what’s happening, understanding trends … |